...On May 31, biosimilar company Oncobiologics Inc. (NASDAQ:ONS) raised $1.5 million through the sale of 5% senior...
...placement. Investors also received warrants to purchase up to 499,500 shares. Oncobiologics Inc. (NASDAQ:ONS), Cranbury, N.J. Julian Zhu Oncobiologics Inc....

...you can do it in your first shot.” Pankaj Mohan, chairman, president and CEO of Oncobiologics Inc....
...U.S. is not a burden. “We have written two protocols,” Mohan said. One protocol gives Oncobiologics...
...wave [of Humira biosimilars] we’ll do that. If everyone is delayed until 2021 or 2022,” Oncobiologics...

...five-year warrants to purchase up to 1.9 million shares at $3. Oncobiologics Inc. (NASDAQ:ONS), Cranbury, N.J. Alicia Parker Oncobiologics Inc....

...LSE:SHP; NASDAQ:SHPG) Ph III Novartis AG (NYSE:NVS; SIX:NOVN) Ph III Pfizer Inc. (NYSE:PFE) Ph III Oncobiologics Inc....

...ALX-0141 , a nanobody against RANKL, in Phase I for bone metastases and postmenopausal osteoporosis. Oncobiologics Inc....

...plc (LSE:ONC) 5/18/16 $15.8 $95.2 $79.7 -16% PhaseRx Inc. (NASDAQ:PZRX) 5/17/16 $18.5 $56.2 $48.4 -14% Oncobiologics Inc....

...year, 18% came with warrants. Even IPOs are being reshaped. On May 12, biosimilar company Oncobiologics Inc....

...units in the placement to existing shareholder Sabby Healthcare Master Fund. Each unit comprises an Oncobiologics...
...at $6.60, and each whole series B warrant for a share at $8.50. In January, Oncobiologics...
...sell 5 million shares at $11-$13. Underwriters are Jefferies, Barclays and Cantor Fitzgerald. This year, Oncobiologics...